Klaus D
Herz. 1987 Apr;12(2):146-55.
Criteria for the diagnosis of exercise hypertension have not yet been established. Published values for blood pressure increase during dynamic exercise in normotensive healthy persons differ greatly dependent on age, sex, heart frequency and load of dynamic exercise. Upper normal systolic values during exercise reach levels between 200 and 230 mm Hg. The incidence of exercise hypertension is therefore reported to range from 1 to 10% of the total population. Follow-up studies show that 10 to 60% of persons with isolated exercise hypertension proceed to chronic arterial hypertension. No results are available on exercise hypertension as a risk factor in contrast to the well-known link between increased systolic and diastolic casual blood pressure and cardiovascular diseases. The development of left-ventricular hypertrophy depends mainly on the average systolic blood pressure during a 24-hour period. Peak values of systolic blood pressure during the day or blood pressure variability are less important. Drug treatment of isolated exercise hypertension is not generally accepted. Non-drug treatment is to be preferred, e.g. weight reduction in overweight, dietary sodium restriction and endurance training. Drug treatment must be considered, if non-drug treatment is unsuccessful and/or risk factors, for example hypercholesterolemia, diabetes, cigarette smoking, or complications of target organs, i.e. coronary heart disease or cerebral infarction, do exist. In antihypertensive treatment of increased exercise blood pressure, the influence of the drugs on the hemodynamic and metabolic parameters must be observed, especially in patients with concomitant coronary heart disease. Increases in blood pressure due to dynamic exercise are better attenuated by antihypertensive drugs than those caused by isometric exercise. The drugs of choice are beta-blockers, preferably beta 1-blockers without ISA. Alternatively, calcium antagonists of the verapamil-type or ACE-inhibitors may be used. In contrast to other antihypertensive drugs, labetalol, calcium antagonists and ACE-inhibitors have no influence on the exercise-induced increase of cardiac index and therefore little effect on the work capacity of the circulatory system.
运动性高血压的诊断标准尚未确立。正常血压的健康人在动态运动期间血压升高的已公布数值因年龄、性别、心率和动态运动负荷的不同而有很大差异。运动期间正常收缩压上限值达到200至230毫米汞柱之间。因此,据报道运动性高血压的发病率占总人口的1%至10%。随访研究表明,10%至60%的单纯运动性高血压患者会发展为慢性动脉高血压。与收缩压和舒张压偶然升高与心血管疾病之间的众所周知的联系相反,目前尚无关于运动性高血压作为危险因素的研究结果。左心室肥厚的发展主要取决于24小时期间的平均收缩压。白天收缩压峰值或血压变异性不太重要。单纯运动性高血压的药物治疗一般未被接受。非药物治疗更可取,例如超重者减轻体重、饮食中限制钠摄入和进行耐力训练。如果非药物治疗不成功和/或存在危险因素,例如高胆固醇血症、糖尿病、吸烟或靶器官并发症,即冠心病或脑梗死,则必须考虑药物治疗。在运动血压升高的抗高血压治疗中,必须观察药物对血流动力学和代谢参数的影响,尤其是在合并冠心病的患者中。与等长运动引起的血压升高相比,降压药物能更好地减轻动态运动引起的血压升高。首选药物是β受体阻滞剂,最好是无内在拟交感活性的β1受体阻滞剂。也可使用维拉帕米型钙拮抗剂或血管紧张素转换酶抑制剂。与其他抗高血压药物不同,拉贝洛尔、钙拮抗剂和血管紧张素转换酶抑制剂对运动诱导的心脏指数增加没有影响, 因此对循环系统的工作能力影响很小。